Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FTC seeks Supreme Court review in K-Dur case

Executive Summary

An appeals court's ruling that a Schering-Plough/Upsher-Smith settlement over generic K-Dur was not anticompetitive "could seriously impede" FTC's law enforcement efforts, the commission says in an Aug. 29 petition for certiorari to the U.S. Supreme Court. FTC seeks review of an Atlanta-based appeals court's March 8 ruling, which stated that the commission should consider the potential exclusionary scope of a brand company's patent when evaluating brand/generic settlements (1"The Pink Sheet" March 14, 2005, p. 31)...

You may also be interested in...

Brand/Generic Settlements Not Necessarily Illegal, DoJ Tells Supreme Court

Payments to generic companies to settle patent challenges under the Hatch-Waxman Act are not necessarily violations of antitrust law, the Office of the Solicitor General says in an amicus curiae brief to the U.S. Supreme Court

FTC Loses K-Dur Antitrust Case; Failure To Consider Schering Patent Cited

The Federal Trade Commission should consider the potential exclusionary scope of a brand-name drug company's patents when evaluating whether a settlement with a generic company is anticompetitive, a federal appeals court ruled March 8

Cybersecurity: Guidance Docs To Come, But Legacy Devices Still A Challenge

Increasing savvy around cybersecurity issues is driving regulators and trade groups to update their approach to the area, speakers from the US FDA and the American Medical Association said at this week’s FDA/CMS Summit.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts